在癌症治疗中对基于RNA的寡核酸的过渡洞察力
Hamed Tabasi1,2, Samaneh Mollazadeh3, Elham Fazeli4
1Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Applied biochemistry and biotechnology
|July 4, 2023
概括
RNA疗法为传统的癌症治疗提供了一个无毒的替代方案. 干扰RNA (siRNA,miRNA) 和信使RNA (mRNA) 平台显示出安全有效的癌症治疗的前景,特别是与其他药物结合使用时.
科学领域:
- 生物技术和生物医学科学 生物技术和生物医学科学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 传统化疗存在重大局限性,原因是严重的,往往不可逆转的副作用会影响重要器官,并可能导致致命的结果.
- 基于RNA的治疗方法的出现提供了一个有前途的替代方案,其特点是其非有毒,非传染性和耐受性良好.
研究的目的:
- 探索用于癌症治疗的各种基于RNA的治疗平台.
- 专门研究小干扰RNA (siRNA),微RNA (miRNA) 和信使RNA (mRNA) 在瘤学中的应用.
- 了解这些RNA模式的治疗机制和潜力.
主要方法:
- 对基于RNA的治疗平台的现有文献进行审查和分析.
- 在癌症治疗的背景下,专注于siRNA,miRNA和mRNA技术.
- 研究涉及RNA与其他治疗药物的联合递送的组合策略.
主要成果:
- 基于RNA的平台显示出作为新型癌症治疗方式的巨大潜力.
- 特定的RNA类型,如siRNA,miRNA和mRNA提供了独特的治疗优势.
- 与其他RNA或药物同时输送RNA可提高治疗的安全性和有效性.
结论:
- 与传统化疗相比,RNA治疗是一种可行的,有利的癌症治疗方法.
- siRNA,miRNA和mRNA技术是推动基于RNA的癌症疗法的关键参与者.
- 基于RNA的组合策略为癌症患者提供了创新和有效的治疗选择.
相关概念视频
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


